#United States #Irvine #Bright Uro #Urodynamics #Glean Registry

Bright Uro Launches Glean® Patient Registry for Urodynamic Intelligence

Introduction

In a significant advancement for urodynamics, Bright Uro, Inc. has announced the launch of the Glean® Patient Registry. This registry is a vital step in transforming care for lower urinary tract dysfunction (LUTD) by facilitating the collection of real-world, de-identified data from patients using the Glean® Urodynamics System. This innovative approach aims to enhance understanding and improve diagnostic capabilities for various bladder conditions.

The Importance of Urodynamics

Urodynamics is essential in evaluating how well the bladder, urethra, and sphincters function in storing and releasing urine. With approximately 80 million Americans affected by LUTD disorders, enhancing diagnostic procedures becomes imperative. The Glean Registry will compile comprehensive data resources that inform clinicians and aid in the development of impactful AI and machine learning algorithms aimed to optimize patient care.

The Glean® Urodynamics System

The Glean® Urodynamics System stands out as the only wireless, catheter-free urodynamics solution available. This revolutionary system significantly improves accuracy, expedites clinical staff proficiency, and provides a more dignified experience for patients undergoing diagnostics. Its unique capabilities are designed to accommodate a broad spectrum of bladder disorders, including conditions such as overactive bladder (OAB), stress urinary incontinence (SUI), benign prostatic hyperplasia (BPH), and neurogenic LUTD (NLUTD).

Data Collection and Research Potential

Enrollment is already underway for existing users of the Glean system, which aims to aggregate patient data and clinician insights into a high-quality informational dataset. Dr. Scott MacDiarmid, the Chief Medical Officer, expressed the ambition behind the registry, stating, "This effort shows our commitment to the advancement of diagnostic tools and data science in urodynamics. The insights gleaned from the registry will allow us to inform and refine our algorithms efficiently."

The intent is to enable the artificial intelligence (AI) and machine learning (ML) platforms known as Urodynamic Intelligence™, enhancing the interpretation of urodynamic test outcomes effectively. Derek Herrera, the Founder and CEO of Bright Uro, elaborated on this capability, adding, "Building Urodynamic Intelligence™ requires reliable data sources, such as Glean, which delivers consistent signals through its innovative sensing technology. This paves the way for creating valuable AI and ML algorithms that can transform our understanding of bladder function."

Commitment to Excellence

With the launch of the Glean Registry, Bright Uro reinforces its commitment to creating evidence-based protocols that set new standards of care in urodynamic evaluations. By developing a robust data repository through the only wireless, catheter-free solution, the company positions itself to become a leading resource provider in the urodynamics marketplace. Practices currently using the Glean Urodynamics System are encouraged to join this pioneering initiative by contacting the company directly.

Conclusion

The Glean Patient Registry is more than just a data collection tool; it represents the future of urodynamics. Bright Uro's efforts towards using technology in healthcare demonstrate a pioneering approach toward enhancing patient care, ultimately aiming to bring about significant advancements in the understanding and treatment of lower urinary tract dysfunction worldwide.

For more information on the Glean Registry and other inquiries, visit GleanUDS.com.